Scarica l'app Stockscreener
0.7086
3.23%
0.0222
Dopo l'orario di chiusura:
.73
0.0214
+3.02%
Jasper Therapeutics Inc Borsa (JSPR) Ultime notizie
Wenru Song Net Worth (2026) - GuruFocus
Kira Pharmaceuticals - The Pharma Letter
Jasper Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
Velan group shifts to passive stake in Jasper (NASDAQ: JSPR) - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Jasper Therapeutics beats Q2 expectations but shares fall after results - Yahoo Finance
Jasper Therapeutics beats earnings expectations but stock falls 4% By Investing.com - Investing.com South Africa
Jasper Therapeutics beats earnings expectations but stock falls 4% - Investing.com
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - marketscreener.com
JSPR Q1 2026 Earnings: 91.94% EPS Beat Signals Cost Discipline, But Stock Slips 8.46%Earnings Season Preview - vinanet.vn
Jasper Therapeutics Q2 EPS of $(0.10) beats estimates - scanx.trade
Jasper Therapeutics (JSPR) narrows Q2 2026 loss, closes Kira deal and $132M PIPE - Stock Titan
Jasper Therapeutics Reports $2.8 Million Second-Quarter Net Loss - Quiver Quantitative
Jasper Therapeutics, Inc. (JSPR) stock: Climbs on Kira Merger and $132M Raise as Pipeline Consolidates - Blockonomi
Jasper Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Jasper Therapeutics Q2 loss per share beats estimates, raises $132 mln - TradingView
Jasper Therapeutics, Inc. 2Q 2026: Net loss $(2.8M), EPS $(0.10) — 10-Q Summary - TradingView
Jasper Therapeutics Reports Q2 2026 Results and Completion of Kira Pharmaceuticals Acquisition - Quiver Quantitative
JSPR Financials: Income Statement, Balance Sheet & Cash Flow | Jasper Therapeutics Inc - Stock Titan
Jasper Therapeutics (JSPR) slashes losses, acquires Kira and raises $132M - Stock Titan
Piper Sandler Initiates Jasper Therapeutics(JSPR.US) With Buy Rating, Announces Target Price $2 - Moomoo
Piper Sandler initiates Jasper Therapeutics stock at overweight By Investing.com - Investing.com Canada
$Jasper Therapeutics (JSPR.US)$ Goodbye - Moomoo
JSPR DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC - The National Law Review
Jasper Therapeutics Inc (JSPR) Stock News Today - TradingKey
Jasper Therapeutics Inc (JSPR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jasper Therapeutics, Inc. expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Jasper Therapeutics (NASDAQ:JSPR): Why Is the Stock Back in Focus as the Latest Update Arrives? - Kalkine Media
JSPR Q1 2026 Earnings: Loss Narrowly Beats Estimates, Shares Surge 12.95%Dividend Increase Stocks - vinanet.vn
Jasper Therapeutics, Inc. (JSPR) Investigation: Bronstein, Gewirt - The National Law Review
JSPR Completes Briquilimab Trial In Chronic Hives, Setting Up Next Risk–Reward Catalyst - TipRanks
Jasper Therapeutics Halts Briquilimab Extension Study in Chronic Urticaria: What Investors Should Know - TipRanks
JSPR Q2'26 Earnings: EPS estimate is (0.25) USD - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Jasper Therap - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Jasper Therapeutics, Inc. announced that it has received $131.996211 million in funding from a group of investors - marketscreener.com
Jasper Therapeutics (JSPR) completes $131.9M Rule 506(b) private equity sale - Stock Titan
Jasper Therapeutics, Inc. (JSPR) awards 7,500 stock options to director - Stock Titan
Jasper Therapeutics (JSPR) awards 7,500 stock options to board director - Stock Titan
Jasper Therapeutics (JSPR) grants 7,500-share stock option to board director - Stock Titan
Jasper Therapeutics (JSPR) grants director option for 7,500 shares - stocktitan.net
Jasper Therapeutics Shareholders Back Board, Auditors, Pay Plan - The Globe and Mail
Jasper Therapeutics (NASDAQ: JSPR) outlines 2026 director, auditor and pay votes - Stock Titan
JSPR Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Jasper Therapeutics, Inc. Revenue Breakdown – NASDAQ:JSPRW - TradingView
Jasper Therapeutics (JSPR) Slips to $0.62 as Stock Tests Key SupportFibonacci Arc - dars.gov.et
Jasper Therapeutics Inc (JSPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jasper Therapeutics Inc (JSPR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Jasper Therapeutics Inc (JSPR) Earnings Date & Reports & Earnings News - TradingKey
Jasper Therapeutics Inc (JSPR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Jasper Therapeutics Inc (JSPR) Institutional Confidence - TradingKey
Jasper Therapeutics Inc (JSPR) Income Statement - TradingKey
Jasper Therapeutics Inc (JSPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
JSPR|Jasper Therapeutics Inc|Price:0.695|Chg%:+0.006 - TradingKey
Jasper Therapeutics (JSPR) Edges Higher Near Key Support LevelMoney Flow - vinanet.vn
JSPR|Jasper Therapeutics Inc|Price:0.690|Chg%:+0.002 - TradingKey
JSPR|Jasper Therapeutics Inc|Price:0.688|Chg%:-0.041 - TradingKey
Jasper Therapeutics Inc (JSPR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Jasper Therapeutics Inc (JSPR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Jasper Therapeutics Inc (JSPR) Cash Flow - TradingKey
JSPR|Jasper Therapeutics Inc|Price:0.650|Chg%:-0.038 - TradingKey
Jasper Therapeutics, Inc. Revenue Breakdown – NASDAQ:JSPR - TradingView
Jasper Therapeutics (JSPR) Slides Further as Shares Test Key Support LevelsStock Analysis - dars.gov.et
Jasper Therapeutics Market Sentiment - Benzinga España
Jasper Therapeutics Inc. (JSPR) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Enterprise value to EBITDA forward of Jasper Therapeutics, Inc. – NASDAQ:JSPRW - TradingView
Jasper Therapeutics (JSPR) CMO lists merger-based stock option awards - Stock Titan
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):